钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者蛋白尿影响的系统评价  

Effect of inhibitors of sodium-glucose co-transporter 2 on albuminuria in patients with type 2 diabetes:a systematic review

作　　者：张欣 杨鹏飞[1] 胡玉栋 袁欣[1] 廖晓辉[1] ZHANG Xin;YANG Pengfei;HU Yudong;YUAN Xin;LIAO Xiaohui(Department of Nephrology,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院肾内科,400010

出　　处：《重庆医学》2021年第2期297-303,共7页Chongqing medicine

摘　　要：目的系统评价钠-葡萄糖共转运蛋白2(SGLT2)抑制剂对2型糖尿病患者蛋白尿的影响。方法检索PubMed、Embase、Cochrane Library数据库收录的从建库至2020年3月发表的关于SGLT2抑制剂对蛋白尿影响的英文文献,并对纳入文献进行质量评价,通过阅读文献获取研究设计、研究对象、临床表现(包括基线资料)、尿清蛋白/肌酐比值(UACR)的效应值、安全性等信息。结果根据检索策略,共纳入文献7篇,均为较大样本的随机对照试验,干预时间至少为12周,分析患者12049例。结果发现,不同剂量、种类的SGLT-2抑制剂药物均有降低2型糖尿病患者蛋白尿的作用,且鲜见严重不良反应。结论合并微-大量蛋白尿的2型糖尿病患者经SGLT2抑制剂治疗后,蛋白尿有显著降低且安全性良好。Objective To evaluate the effects of sodium-glucose co-transporter 2(SGLT2)inhibitors on albuminuria in type 2 diabetic patients.Methods English literatures on the effect of SGLT2 inhibitors on albuminuria were retrieved from PubMed,Embase and Cochrane Library databases from establishment to March 2020,and the quality of the included literature was evaluated.Research design,subjects,clinical manifestations(including baseline data),effect of urinary albumin/creatinine ratio(UACR)and other information were obtained by reading the literatures.Results According to the retrieval strategy,7 articles were included totally,all of which were randomized controlled trials with a large number of samples.The intervention time was at least 12 weeks,and 12049 patients were analyzed.It was found that different doses and types of SGLT-2 inhibitors had the effect of reducing albuminuria in patients with type 2 diabetes and severe adverse reaction were rarely seen.Conclusion After treatment with SGLT2 inhibitors,the level of albuminuria decreased significantly in patients with type 2 diabetes mellitus combined with micro-macro albuminuria,and the safety profile is good.

关 键 词：糖尿病 2型 钠-葡萄糖协同转运蛋白2抑制剂 蛋白尿 尿清蛋白/肌酐比值 系统评价 

分 类 号：R587.2[医药卫生—内分泌]